GWAS

:   genome wide association studies

rSNP

:   regulatory SNP

TFBRs

:   transcription factor binding regions

CIRs

:   chromatin interactive regions

lncRNAs

:   long non-coding RNA regions

TADs

:   topologically associated domains

circRNAs

:   circular RNAs

PTMs

:   protein post-translational modifications

GO

:   gene ontology

SCZ

:   Schizophrenia

INTRODUCTION
============

Schizophrenia (SCZ) is a chronic and severe mental disorder, characterized by psychosis, apathy and withdrawal, and cognitive impairment. Depression, anxiety, and substance abuse are additional mental health problems of SCZ condition. The symptoms of SCZ typically appear gradually, start between ages 16 and 30, and never resolve in many cases. About 1% of the population is affected by SCZ during their lifetimes, which is associated with substantial morbidity and mortality, as well as personal and societal costs \[[@r1], [@r2]\]. Moreover, SCZ is ranked among the top 25 leading causes of disability worldwide \[[@r3]\].

SCZ is a multi-factorial disease, and its occurrence depends on environmental and genetic factors. The high heritability of SCZ points to a major role for inherited genetic variants in the etiology of SCZ, with estimated heritability up to 80% \[[@r1], [@r2]\]. In recent years, considerable progress has been done in the genetic studies of SCZ \[[@r4]\]. Multiple susceptibility genes have been identified for SCZ \[[@r2], [@r5]\], such as NRG1 \[[@r5]\], DISC1 \[[@r5]\] and DRD2 \[[@r2]\]. Major histocompatibility complex (MHC) \[[@r1]\] on chromosome 6p is the most significant region for SCZ, which contains many markers reaching genome-wide significance \[[@r4]\]. However, the genetic mechanism of SCZ remains largely unknown.

Genome-wide association studies (GWAS) have great power to identify susceptibility genetic loci associated with complex diseases. Over the years, a number of creditable candidate genes for SCZ has been identified, largely by GWAS \[[@r2]\]. Because a stringent threshold requires a huge sample size to reliably identify risk genes, the significant loci identified by GWAS are usually limited and functionally independent, providing limited information for the mechanism studies of SCZ. Moreover, a large part of genetic variants detected by GWAS are located in non-coding chromosomal regions \[[@r4]\]. It is usually confusing how these non-coding regions implicated would be involved in the development of SCZ.

Functional SNPs located in protein-coding and non-coding genes are named regulatory single nucleotide polymorphisms (rSNPs), which usually have major impacts on gene functions \[[@r6]\]. They mainly include transcription factor binding regions (TFBRs), chromatin interactive regions (CIRs), topologically associated domains (TADs), long non-coding RNAs (lncRNAs) coding regions, and circular RNA (circRNA) regions. Additionally, some SNPs located in the protein coding regions can alter protein post-translational modifications (PTMs) \[[@r7]\], such as phosphorylation, methylation, acetylation, ubiquitination, and glycosylation. The implication of rSNPs in the development of complex diseases has been well documented in previous studies \[[@r8]--[@r10]\]. Integrating GWAS and functional rSNPs annotation information have improved GWAS power and provided novel clues for the genetic studies of complex diseases \[[@r11]--[@r13]\], such as periodontal diseases \[[@r13]\] and breast cancer \[[@r12]\]. To the best of our knowledge, limited efforts have been paid to explore the functional relevance of rSNPs with SCZ.

In this study, we conducted a large-scale integrative analysis of two GWAS datasets of SCZ with functional annotation datasets of rSNPs. The significant SNPs identified by the two GWAS were first annotated to obtain SCZ-associated rSNPs and their target gene and proteins, respectively. We then compared the integrative analysis results to identify the common rSNPs and their target gene and proteins, shared by the two GWAS of SCZ. Finally, DAVID tool was used to conduct gene ontology (GO) and pathway enrichment analysis of the identified target genes and proteins shared by the two GWAS of SCZ.

RESULTS
=======

Analysis results of GWAS and rSNP annotation datasets
-----------------------------------------------------

For TFBRs, CIRs, lncRNAs regions, TADs and circRNAs, we identified 1,499 SCZ associated rSNPs, corresponding to 35 genes, such as FOS (*P value* = 2.18×10^-20^), GABBR1 (*P value* = 2.18×10^-20^), MDK (*P value* = 1.89×10^-10^) and ATXN1 (*P value* = 5.22×10^-21^). For PTM, we detected 43 rSNPs, corresponding to 18 genes, such as HLA-DQA1 (*P value* = 1.98×10^-10^), HLA-DRB1 (*P value* = 1.36×10^-12^) and ZSCAN31 (*P value* = 8.78×10^-10^) ([Table 1](#t1){ref-type="table"}).

###### List of SCZ associated rSNPs and their target regulatory genes and proteins shared by both SCZ 1 and SCZ 2.

  ------------- ----------- ---------------------------------------------- ---------------
  **SNP**       **Gene**    **SNP-related regulatory elements**            ***P value***
  rs35001169    HIST1H3J    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   7.40× 10^-27^
  rs35001169    HIST1H2AM   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   7.40× 10^-27^
  rs35819751    MIR3143     TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   9.52× 10^-27^
  rs66462181    HIST1H4A    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.06× 10^-26^
  rs17695758    DNAH8       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.52× 10^-26^
  rs141342723   HIST1H2BL   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.82× 10^-26^
  rs13209332    HIST1H2AK   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.10× 10^-26^
  rs2232423     ZSCAN12     PTMs                                           1.71× 10^-23^
  rs33932084    PGBD1       PTMs                                           5.00× 10^-23^
  rs41266839    BTN3A1      PTMs                                           4.77× 10^-22^
  rs34788973    OR2B2       PTMs                                           1.87× 10^-21^
  rs34197618    ATXN1       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.22× 10^-21^
  rs41266779    FOS         TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    HIST1H2BK   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    NUP153      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    PKHD1       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    CLIC5       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    DCDC2       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    GABBR1      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    PRIM2       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    ANKH        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs41266779    HIST1H2AH   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.18× 10^-20^
  rs35050608    MBOAT1      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.37× 10^-20^
  rs35506517    LY86        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.25× 10^-20^
  rs9393718     HIST1H2BJ   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.32× 10^-20^
  rs35555795    BTN1A1      PTMs                                           9.83× 10^-17^
  rs79780963    RNU1-60P    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   7.51× 10^-16^
  rs13216828    BTN3A2      PTMs                                           1.59× 10^-15^
  rs9986596     ZKSCAN4     PTMs                                           5.51× 10^-15^
  rs3891176     HLA-DQB1    PTMs                                           3.29× 10^-14^
  rs11693528    BMPR2       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.62× 10^-14^
  rs16891235    HIST1H1A    PTMs                                           1.59× 10^-13^
  rs769949      PLCL1       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.10× 10^-13^
  rs853678      ZSCAN31     PTMs                                           3.42× 10^-13^
  rs281786      MPP4        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.92× 10^-13^
  rs281786      AOX1        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.92× 10^-13^
  rs35220450    RAPH1       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.05× 10^-13^
  rs35220450    INO80D      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.05× 10^-13^
  rs281760      AOX2P       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.71× 10^-13^
  rs10734901    ATP6V0A2    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.83× 10^-13^
  rs3098341     BOLL        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.89× 10^-13^
  rs10431750    KLC1        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.69× 10^-13^
  rs56155997    PDE11A      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.92× 10^-13^
  rs34525648    SLC17A2     PTMs                                           1.22× 10^-12^
  rs16822516    HLA-DRB1    PTMs                                           1.36× 10^-12^
  rs71417869    CDC42BPB    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.02× 10^-12^
  rs2075800     HSPA1L      PTMs                                           6.00× 10^-11^
  rs35324223    MDK         TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.89× 10^-10^
  rs707962      HLA-DQA1    PTMs                                           1.98× 10^-10^
  rs115817940   HLA-DRB5    PTMs                                           3.46× 10^-10^
  rs13201753    ZKSCAN3     PTMs                                           8.78× 10^-10^
  rs950169      ADAMTSL3    PTMs                                           9.17× 10^-10^
  rs13107325    SLC39A8     PTMs                                           5.03× 10^-9^
  ------------- ----------- ---------------------------------------------- ---------------

Note: TFBRs, transcription factor binding regions; CIRs, chromatin interactive regions; TADs, topologically associated domains; PTMs, protein post-translational modifications.

GO enrichment analysis
----------------------

GO enrichment analysis identified 15 GO terms enriched in the identified target genes of TFBRs, CIRs, lncRNAs, TADs and circRNAs, such as GO:0000786\~nucleosome (*P value* = 1.84×10^-10^), GO:0046982\~protein heterodimerization activity (*P value* = 5.97×10^-7^), GO:0000788\~nuclear nucleosome (*P value* = 5.63×10^-5^) and GO:0006334\~nucleosome assembly (*P value* = 5.70×10^-5^). For PTMs, we identified 37 SCZ-associated GO terms, such as GO:0002504\~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (*P value* = 4.79×10^-7^), GO:0042613\~MHC class II protein complex (*P value* = 1.03×10^-6^), GO:0042605\~peptide antigen binding (*P value* = 2.26×10^-6^) and GO:0071556\~integral component of lumenal side of endoplasmic reticulum membrane (*P value* = 2.43×10^-6^) ([Table 2](#t2){ref-type="table"}).

###### List of SCZ associated gene ontology terms shared by both SCZ 1 and SCZ 2.

  ------------ -------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------
  **Term**     **Term description**                                                                         **SNP-related regulatory elements**            ***P value***
  GO:0000786   nucleosome                                                                                   TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.84× 10^-10^
  GO:0002504   Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II    PTMs                                           4.79× 10^-7^
  GO:0046982   protein heterodimerization activity                                                          TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.97× 10^-7^
  GO:0042613   MHC class II protein complex                                                                 PTMs                                           1.03× 10^-6^
  GO:0042605   Peptide antigen binding                                                                      PTMs                                           2.26× 10^-6^
  GO:0071556   Integral component of lumenal side of endoplasmic reticulum membrane                         PTMs                                           2.43× 10^-6^
  GO:0030658   Transport vesicle membrane                                                                   PTMs                                           5.57× 10^-6^
  GO:0030669   Clathrin coated endocytic vesicle membrane                                                   PTMs                                           7.03× 10^-6^
  GO:0002381   Immunoglobulin production involved in immunoglobulin mediated immune response                PTMs                                           8.50× 10^-6^
  GO:0050852   T cell receptor signaling pathway                                                            PTMs                                           9.71× 10^-6^
  GO:0012507   ER to Golgi transport vesicle membrane                                                       PTMs                                           1.45× 10^-5^
  GO:0002455   Humoral immune response mediated by circulating immunoglobulin                               PTMs                                           1.78× 10^-5^
  GO:0019882   Antigen processing and presentation                                                          PTMs                                           1.81× 10^-5^
  GO:0030666   Endocytic vesicle membrane                                                                   PTMs                                           2.98× 10^-5^
  GO:0060333   Interferon gamma mediated signaling pathway                                                  PTMs                                           3.90× 10^-5^
  GO:0031295   T cell costimulation                                                                         PTMs                                           5.17× 10^-5^
  GO:0000788   nuclear nucleosome                                                                           TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.63× 10^-5^
  GO:0006334   nucleosome assembly                                                                          TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.70× 10^-5^
  GO:0032588   Trans Golgi network membrane                                                                 PTMs                                           5.92× 10^-5^
  GO:0019886   Antigen processing and presentation of exogenous peptide antigen via MHC class II            PTMs                                           8.46× 10^-5^
  GO:0032395   MHC class II receptor activity                                                               PTMs                                           8.78× 10^-5^
  GO:0003677   DNA binding                                                                                  TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.20× 10^-4^
  GO:0005737   cytoplasm                                                                                    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   5.83× 10^-4^
  GO:0043565   Sequence specific DNA binding                                                                PTMs                                           1.19× 10^-3^
  GO:0005765   Lysosomal membrane                                                                           PTMs                                           1.96× 10^-3^
  GO:2001179   Regulation of interleukin 10 secretion                                                       PTMs                                           2.86× 10^-3^
  GO:0006342   chromatin silencing                                                                          TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.91× 10^-3^
  GO:0032673   Regulation of interleukin 4 production                                                       PTMs                                           3.81× 10^-3^
  GO:0072643   Interferon gamma secretion                                                                   PTMs                                           6.65× 10^-3^
  GO:0006955   Immune response                                                                              PTMs                                           6.87× 10^-3^
  GO:0003700   Transcription factor activity, sequence specific DNA binding                                 PTMs                                           1.10× 10^-2^
  GO:0042088   T helper 1 type immune response                                                              PTMs                                           1.14× 10^-2^
  GO:0016020   Membrane                                                                                     PTMs                                           1.17× 10^-2^
  GO:0016045   Detection of bacterium                                                                       PTMs                                           1.23× 10^-2^
  GO:0002437   Inflammatory response to antigenic stimulus                                                  PTMs                                           1.42× 10^-2^
  GO:0000139   Golgi membrane                                                                               PTMs                                           1.64× 10^-2^
  GO:0031047   gene silencing by RNA                                                                        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   1.67× 10^-2^
  GO:0042405   nuclear inclusion body                                                                       TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   2.19× 10^-2^
  GO:0032689   Negative regulation of interferon gamma production                                           PTMs                                           2.64× 10^-2^
  GO:0035774   Positive regulation of insulin secretion involved in cellular response to glucose stimulus   PTMs                                           2.73× 10^-2^
  GO:0016021   Integral component of membrane                                                               PTMs                                           2.81× 10^-2^
  GO:0010507   Negative regulation of autophagy                                                             PTMs                                           3.38× 10^-2^
  GO:0007040   Lysosome organization                                                                        PTMs                                           3.38× 10^-2^
  GO:0042130   Negative regulation of T cell proliferation                                                  PTMs                                           3.47× 10^-2^
  GO:0051262   Protein tetramerization                                                                      PTMs                                           3.75× 10^-2^
  GO:0005654   nucleoplasm                                                                                  TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.77× 10^-2^
  GO:0005887   Integral component of plasma membrane                                                        PTMs                                           3.81× 10^-2^
  GO:0007214   gamma-aminobutyric acid signaling pathway                                                    TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.86× 10^-2^
  GO:0070062   extracellular exosome                                                                        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   3.98× 10^-2^
  GO:0000790   nuclear chromatin                                                                            TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.24× 10^-2^
  GO:0002227   innate immune response in mucosa                                                             TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.38× 10^-2^
  GO:0032200   telomere organization                                                                        TFBRs, CIRs, lncRNAs regions, TADs, circRNAs   4.72× 10^-2^
  ------------ -------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------

Note: TFBRs, transcription factor binding regions; CIRs, chromatin interactive regions; TADs, topologically associated domains; PTMs, protein post-translational modifications.

Pathway enrichment analysis
---------------------------

For TFBRs, CIRs, lncRNAs, TADs and circRNAs, we identified 3 pathways associated with SCZ, including ha05322:Systemic lupus erythematosus (*P value* = 3.77×10^-8^), hsa05034:Alcoholism (*P value* = 2.57×10^-7^) and hsa05203:Viral carcinogenesis (*P value* = 1.78×10^-2^). For PTMs, we identified 21 pathways associated with SCZ, such as hsa04612:Antigen processing and presentation (*P value* = 6.82×10^-8^), hsa05310:Asthma (*P value* = 7.44×10^-7^), hsa05332:Graft-versus-host disease (*P value* = 1.00×10^-6^) and hsa04672:Intestinal immune network for IgA production (*P value* = 2.96×10^-6^) ([Table 3](#t3){ref-type="table"}).

###### List of SCZ associated pathways shared by both SCZ 1 and SCZ 2.

  ---------------------------------------------- ------------- ---------------------------------------------------- ---------------
  **Term description**                           **Term ID**   **SNP-related regulatory elements**                  ***P value***
  Systemic lupus erythematosus                   hsa05322      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs, PTMs   3.37× 10^-8^
  Antigen processing and presentation            hsa04612      PTMs                                                 6.82× 10^-8^
  Alcoholism                                     hsa05034      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs         2.57× 10^-7^
  Toxoplasmosis                                  hsa05145      PTMs                                                 3.06× 10^-7^
  Asthma                                         hsa05310      PTMs                                                 7.44× 10^-7^
  Graft-versus-host disease                      hsa05332      PTMs                                                 1.00× 10^-6^
  Allograft rejection                            hsa05330      PTMs                                                 1.42× 10^-6^
  Influenza A                                    hsa05164      PTMs                                                 1.94× 10^-6^
  Type I diabetes mellitus                       hsa04940      PTMs                                                 2.10× 10^-6^
  Intestinal immune network for IgA production   hsa04672      PTMs                                                 2.96× 10^-6^
  Autoimmune thyroid disease                     hsa05320      PTMs                                                 4.03× 10^-6^
  Staphylococcus aureus infection                hsa05150      PTMs                                                 4.52× 10^-6^
  Viral myocarditis                              hsa05416      PTMs                                                 5.33× 10^-6^
  Inflammatory bowel disease (IBD)               hsa05321      PTMs                                                 7.58× 10^-6^
  Leishmaniasis                                  hsa05140      PTMs                                                 1.04× 10^-5^
  Rheumatoid arthritis                           hsa05323      PTMs                                                 1.99× 10^-5^
  Epstein-Barr virus infection                   hsa05169      PTMs                                                 5.30× 10^-5^
  Systemic lupus erythematosus                   hsa05322      PTMs                                                 7.03× 10^-5^
  Cell adhesion molecules (CAMs)                 hsa04514      PTMs                                                 8.36× 10^-5^
  Phagosome                                      hsa04145      PTMs                                                 9.84× 10^-5^
  Tuberculosis                                   hsa05152      PTMs                                                 1.61× 10^-4^
  Herpes simplex infection                       hsa05168      PTMs                                                 1.78× 10^-4^
  HTLV-I infection                               hsa05166      PTMs                                                 4.71× 10^-4^
  Viral carcinogenesis                           hsa05203      TFBRs, CIRs, lncRNAs regions, TADs, circRNAs         1.78× 10^-2^
  ---------------------------------------------- ------------- ---------------------------------------------------- ---------------

Note: TFBRs, transcription factor binding regions; CIRs, chromatin interactive regions; TADs, topologically associated domains; PTMs, protein post-translational modifications.

DISCUSSION
==========

Considering that most of SCZ variants identified by GWAS were not causal, integration of the GWAS results with functional rSNPs information is a powerful approach to discover novel candidate genes for SCZ \[[@r4]\]. To evaluate the roles of rSNPs in the pathogenesis of SCZ, we conducted a large-scale integrative genomics analysis of two GWAS datasets of SCZ with functional annotation datasets of rSNPs. We identified multiple candidate genes, GO terms, and biological pathways for SCZ. Our study results support the functional importance of rSNPs in the genetic mechanism of SCZ, and provide novel clues for understanding the genetic architecture of SCZ.

We identified several candidate genes for SCZ, such as FOS, GABBR1, MDK, ATXN1 and ZSCAN31. FOS is classified as one of the immediate early genes (IEGs), which encode not only transcription factors, but also a much wider variety of proteins, including signaling molecules, growth factors and cytoskeletal proteins \[[@r14]\]. Alteration in the expression of IEGs is linked to neuron generation and neuronal cell death. Nadia Cattane et al. have reported that FOS was significantly upregulated in the fibroblasts of SCZ patients \[[@r14]\]. Defects in synaptic plasticity are involved in the pathophysiology of SCZ. Interestingly, SNPs either protective (rs1063169) or positively associated with SCZ (rs7101T) were identified, showing transcription factor c-fos was important in the regulation of synaptic plasticity \[[@r15]\]. Huang et al. observed high FOS expression in non-neural peripheral samples and low FOS expression in the brain tissues of SCZ patients compared with healthy controls, which suggests that FOS is a sensitive marker for SCZ \[[@r16]\]. In addition, detection of FOS in blood samples may be helpful for SCZ diagnosis \[[@r16]\]. These combined results support the functional relevance of FOS with SCZ \[[@r14]--[@r16]\], which is consistent with our study results.

GABBR1 is another SCZ-associated gene identified by this study. γ-aminobutyric acid~B~ (GABA~B~) is an inhibitory transmitter molecule acting at neuronal synapses. Functional GABA~B~ receptor requires both the GABBR1 and GABBR2 subunits. GABA~B~ receptor can modulate the release of a number of neurotransmitters, including dopamine, serotonin, noradrenaline, somatostatin, glutamate and GABA \[[@r17]\]. Interestingly, the reduction of GABBR1 in pyramidal cells, and consequent reduction of GABA~B~ receptors, can result in the dysfunction of inhibitory mechanism and increase signal output \[[@r18]\]. Previous studies have also observed association between GABBR1 and SCZ. Fatemi et al. observed a significant reduction of GABBR1 protein in the lateral cerebellum of the subjects with SCZ, bipolar disorder, and major depression \[[@r17]\]. In addition, Zai et al. conducted a case-control study and detected a positive association between GABBR1 and SCZ \[[@r19]\].

Genetic variation in a region on chromosome 11 that contains MDK was significantly associated with SCZ \[[@r20]\]. In addition, MDK also accumulated in senile plaques in the hippocampus of patients with Alzheimer's disease \[[@r20], [@r21]\]. Notably, ATXN1 serves as one of the hub genes in the protein-protein interaction network containing many known SCZ risk genes \[[@r22]\]. Actually, ATXN1 is highly expressed in prefrontal cortex, and SCZ patients had significantly decreased ATXN1 expression \[[@r22]\]. In addition, Takeo Saito et al. have revealed an association of rs7779855 in ZSCAN31 with SCZ \[[@r23]\].

GO analysis detected several GO terms for SCZ. One important finding of this study is the disclosure of the MHC class II protein complex (GO:0042613), a class of MHC molecules like human leukocyte antigens HLA-DQA1 and HLA-DQB1, which present antigens to CD4-positive T-lymphocytes. The association between SCZ and the immune system has been repeatedly revealed in genetic, epidemiological and post mortem studies \[[@r24]\]. The protein encoded by HLA-DQA1 gene binds to the protein encoded by HLA-DQB1. Together, they form a functional protein complex called an antigen-binding DQαβ heterodimer, which displays foreign peptides to immune system to trigger body\'s immune response. Interestingly, HLA alleles were previously shown to be associated with SCZ risk \[[@r25]\]. rs9272105 within HLA-DQA1 explained 1--3% of variation in attentional control, and to a lesser extent, premorbid intelligence quotient in psychotic patients \[[@r26]\]. Additionally, rs9272105 within HLA-DQA1 was also individually associated with variation in neuropsychological function \[[@r26]\]. It has been demonstrated that the level of HLA-DRB1 in SCZ was decreased in peripheral blood samples in contrast with increased level in prefrontal cortex \[[@r27]\]. Moreover, HLA-DPA1 and CD74, which are integral components of the MHC Class II protein complex, were both reduced in hippocampus, amygdala, and dorsolateral prefrontal cortex regions in SCZ \[[@r28]\].

T helper 1 type immune response (GO:0042088) is another significant GO term detected by this study. Delayed hypersensitivity reaction is the classic cell-mediated immune response with sensitized T helper-1 cells. Michael et al. found an attenuated skin reactivity to various antigens in SCZ patients \[[@r29]\]. They also observed significantly diminished responses of schizophrenics to antigen stimulation with tetanus and diptheria antigen presentation \[[@r29]\]. Significantly increased serum level of interleukin-18, a cytokine known to activate T helper 1 type cells in immune responses, has been previously observed in SCZ patients \[[@r30]\].

In addition, we also identified several other GO terms associated with SCZ, such as Golgi membrane (GO:0000139) and GABA signaling pathway (GO:0007214). Previously, it was shown that differentially expressed genes related to Golgi apparatus, vesicular transport and membrane association were over-represented in SCZ \[[@r31]\]. In line, Devor et al. identified a large number of GABA-associated genes for SCZ \[[@r32]\].

The involvement of cell adhesion molecules (CAMs) in the pathophysiology of SCZ has long been hypothesized. In this study, CAMs (hsa04514) pathway was detected for SCZ. The CAMs pathway is implicated in a variety of neurocognitive processes, including memory and attention-related reaction time. Multiple CAM genes has been reported to be associated with SCZ risk \[[@r26]\]. Neural CAMs are very important members of the exclusive group of the molecules responsible for precise wiring of nervous system. Neural CAMs serve as ''glue'' in cell-to-cell adhesion and contact-mediated attraction \[[@r33]\]. They can interact with numerous matrix components, and are involved in many aspects of neuronal development, synaptogenesis, and myelination, which guide brain morphology and support highly-coordinated brain activity \[[@r33]\]. Cerebrospinal fluid neuronal CAMs were significantly increased in SCZ patients \[[@r34]\]. Additionally, the plasma levels of intercellular adhesion molecule-1 was also elevated in SCZ patients \[[@r35]\]. Honer et al. found that syntaxin immunoreactivity in the cingulate cortex from schizophrenics was increased, along with neural CAMs and the CAMs to synaptophysin ratio \[[@r36]\]. Besides, it has been reported that L1 cell adhesion molecule interaction was involved in neuronal function \[[@r37]\].

Another interesting SCZ associated pathway is alcoholism (hsa05034). Recent studies have suggested that alcoholism has a wide-reaching influence on the clinical course of SCZ, contributing to shape abnormalities in hippocampus and subcortical shape differences \[[@r38]\]. We also observed that systemic lupus erythematosus (SLE) (hsa05322) was associated with SCZ. Despite the fact that SCZ is not classified as a typical autoimmune diseases, the dysregulation of the immune system cannot be excluded \[[@r39], [@r40]\]. Interestingly, DNA and myelin basic protein (MBP)-hydrolyzing antibodies, which play an important harmful role in SLE pathogenesis, were also detected in the sera of SCZ patients. In addition, light chains of IgGs from SCZ patients were similar to those of SLE patients \[[@r41]\].

The majority of SNPs identified by GWAS are enriched in non-coding regions \[[@r4]\], and contribute to complex traits and diseases through various molecular mechanisms. These include effects on transcription factor binding affinities, which can result in differential gene expression \[[@r11]\]. However, significant loci identified by GWAS have rarely been tracked to causal polymorphisms thus far. Integrative analysis of GWAS with functional rSNPs is helpful to improve GWAS power and provide novel clues for pathogenetic studies of SCZ. Notably, the functional SNPs data can assist to exclude unlikely genes/loci, effectively reducing the number of tests needed for unbiased searches across the genome, thus, improving the power to discover novel causal loci \[[@r4]\]. To the best of our knowledge, this is the first large-scale integrative analysis of GWAS and rSNPs for SCZ. The implication of rSNPs in the development of SCZ was systematically investigated considering TFBRs, CIRs, lncRNAs regions, TADs, circRNAs, and PTMs in our study. Nevertheless, one limitation of this study should be noted. The SCZ-associated SNP sets were driven from previous GWAS. The accuracy of our integrative analysis may be affected by the power of previous GWAS of SCZ. Therefore, further studies are warranted to confirm our findings.

In conclusion, we conducted a large-scale integrative genomics analysis of two GWAS datasets of SCZ with functional annotation datasets of rSNPs to explore the genetic basis of rSNPs in the pathogenesis of SCZ. We observed multiple candidate genes, GO terms and pathways for SCZ. We hope that our study results could provide novel clues for the pathogenic and therapic studies of SCZ.

MATERIALS AND METHODS
=====================

The first GWAS dataset of SCZ (SCZ1)
------------------------------------

A large GWAS meta-analysis data of SCZ was driven from the Psychiatric Genomics Consortium (PGC) \[[@r42]\], totally containing 33,426 SCZ cases and 32,541 controls. Genotypes from all studies were processed by the PGC using unified quality control procedures followed by imputation of SNPs and insertion-deletions using the 1000 Genomes Project reference panel \[[@r43]\]. Quality control and imputation were performed on each of the study cohort datasets, according to the standard procedures established by the PGC \[[@r42]\]. Genotype imputation was performed using the pre-phasing/imputation stepwise approach implemented in IMPUTE2 \[[@r44]\] and SHAPEIT \[[@r45]\]. The imputation reference set consists of 2,186 phased haplotypes from the full 1000 Genomes Project dataset. Logistic regression was conducted to control for 13 components of ancestry, study sites and genotyping platform. Detailed description of sample characteristics, experimental design, statistical analysis and quality control can be found in the previous studies \[[@r42]\].

The second GWAS dataset of SCZ (SCZ2)
-------------------------------------

Another independent GWAS data of SCZ \[[@r2]\] was used here. Briefly, this GWAS included 36,989 SCZ cases and 113,075 controls, from 49 ancestry matched, non-overlapping case-control samples (46 of European and three of East Asian ancestry, 34,241 cases and 45,604 controls) and 3 family-based samples of European ancestry (1,235 parent affected-offspring trios). Genotypes from all studies were processed by the PGC using unified quality control procedures. The 1000 Genomes Project reference panel was used for SNPs imputation \[[@r43]\]. In each sample, association testing was conducted using imputed SNP dosages and principal components to control for population stratification. After quality control (imputation INFO score ≥ 0.6, MAF ≥ 0.01, and successfully imputed in ≥ 20 samples), they considered around 9.5 million variants. An inverse-weighted fixed effects model was used for final meta-analysis. Detailed description of sample characteristics, experimental design, statistical analysis and quality control can be found in the previous study \[[@r2]\].

rSNPs annotation datasets
-------------------------

The rSNPs annotation information were driven from the rSNPBase 3.1 database (<http://rsnp3.psych.ac.cn>) \[[@r46]\] and the AWESOME database (<http://www.awesome-hust.com>) \[[@r7]\]. rSNPBase 3.1 provided rich functional annotation for human SNP-related regulatory elements and their target regulatory genes, including TFBRs, CIRs, mature microRNA (miRNA) regions, predicted miRNA target sites, lncRNA regions, TADs and circRNAs. AWESOME database is an analysis tool that systematically evaluates the role of SNPs on nearly all kinds of PTMs based on 20 available tools. They construct a comprehensive platform to collect and integrate SNPs and multiple PTM information, utilizing 24 published database or tools. 1,043,608 germline missense variants from the dbSNP was used and each SNP was matched with its protein sequence in AWESOME. Detailed description of the two rSNPs annotation database can be found in the published studies \[[@r7], [@r46]\].

Statistical analysis
--------------------

The significant SNPs with GWAS *P value* \< 5.0 × 10^-8^ were selected from the two GWAS of SCZ (SCZ1 and SCZ2). The selected SCZ-associated SNPs were then annotated by the rSNPBase 3.1 database \[[@r46]\] and the AWESOME database to obtain SCZ associated rSNPs and their target regulatory genes and proteins. We then compared the integrative analysis results to identify the common rSNPs and their target genes and proteins shared by the two GWAS of SCZ. To explore the functional relevance of identified target regulatory genes and proteins with SCZ, GO and pathway enrichment analyses of the identified common target genes and proteins shared by the SCZ1 and SCZ2 were performed by the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool \[[@r47]\].
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